Haematologica (Aug 2023)

Phenotypic profiling of CD34<sup>+</sup> cells by advanced flow cytometry improves diagnosis of juvenile myelomonocytic leukemia

  • Cristina Bugarin,
  • Laura Antolini,
  • Chiara Buracchi,
  • Sergio Matarraz,
  • Tiziana Angela Coliva,
  • Vincent H. van der Velden,
  • Tomasz Szczepanski,
  • Elaine Sobral da Costa,
  • Alita van der Sluijs,
  • Michaela Novakova,
  • Ester Mejstrikova,
  • Stefan Nierkens,
  • Fabiana Vieira de Mello,
  • Paula Fernandez,
  • Carmen Aanei,
  • Łukasz Sędek,
  • Luisa Strocchio,
  • Riccardo Masetti,
  • Laura Sainati,
  • Jan Philippé,
  • Maria Grazia Valsecchi,
  • Franco Locatelli,
  • Jacques J.M. van Dongen,
  • Andrea Biondi,
  • Alberto Orfao,
  • Giuseppe Gaipa

DOI
https://doi.org/10.3324/haematol.2023.282805
Journal volume & issue
Vol. 109, no. 2

Abstract

Read online

Diagnostic criteria for juvenile myelomonocytic leukemia (JMML) are currently well defined, however in some patients diagnosis still remains a challenge. Flow cytometry is a well established tool for diagnosis and follow-up of hematological malignancies, nevertheless it is not routinely used for JMML diagnosis. Herewith, we characterized the CD34+ hematopoietic precursor cells collected from 31 children with JMML using a combination of standardized EuroFlow antibody panels to assess the ability to discriminate JMML cells from normal/reactive bone marrow cell as controls (n=29) or from cells of children with other hematological diseases mimicking JMML (n=9). CD34+ precursors in JMML showed markedly reduced B-cell and erythroid-committed precursors compared to controls, whereas monocytic and CD7+ lymphoid precursors were significantly expanded. Moreover, aberrant immunophenotypes were consistently present in CD34+ precursors in JMML, while they were virtually absent in controls. Multivariate logistic regression analysis showed that combined assessment of the number of CD34+CD7+ lymphoid precursors and CD34+ aberrant precursors or erythroid precursors had a great potential in discriminating JMMLs versus controls. Importantly our scoring model allowed highly efficient discrimination of truly JMML versus patients with JMML-like diseases. In conclusion, we show for the first time that CD34+ precursors from JMML patients display a unique immunophenotypic profile which might contribute to a fast and accurate diagnosis of JMML worldwide by applying an easy to standardize single eight-color antibody combination.